198 related articles for article (PubMed ID: 36547981)
1. Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide.
Garcia-Argibay M; Hiyoshi A; Fall K; Montgomery S
JAMA Netw Open; 2022 Dec; 5(12):e2248135. PubMed ID: 36547981
[TBL] [Abstract][Full Text] [Related]
2. Association of Suicidality and Depression With 5α-Reductase Inhibitors.
Welk B; McArthur E; Ordon M; Anderson KK; Hayward J; Dixon S
JAMA Intern Med; 2017 May; 177(5):683-691. PubMed ID: 28319231
[TBL] [Abstract][Full Text] [Related]
3. Suicidal risk associated with finasteride versus dutasteride among men treated for benign prostatic hyperplasia: nationwide cohort study.
Laanani M; Weill A; Jollant F; Zureik M; Dray-Spira R
Sci Rep; 2023 Mar; 13(1):5308. PubMed ID: 37002313
[TBL] [Abstract][Full Text] [Related]
4. Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study.
Wei L; Lai EC; Kao-Yang YH; Walker BR; MacDonald TM; Andrew R
BMJ; 2019 Apr; 365():l1204. PubMed ID: 30971393
[TBL] [Abstract][Full Text] [Related]
5. Lack of Association between 5α-Reductase Inhibitors and Depression.
Dyson TE; Cantrell MA; Lund BC
J Urol; 2020 Oct; 204(4):793-798. PubMed ID: 32294395
[TBL] [Abstract][Full Text] [Related]
6. Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride.
Nguyen DD; Marchese M; Cone EB; Paciotti M; Basaria S; Bhojani N; Trinh QD
JAMA Dermatol; 2021 Jan; 157(1):35-42. PubMed ID: 33175100
[TBL] [Abstract][Full Text] [Related]
7. 5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer.
Azoulay L; Eberg M; Benayoun S; Pollak M
JAMA Oncol; 2015 Jun; 1(3):314-20. PubMed ID: 26181177
[TBL] [Abstract][Full Text] [Related]
8. The Cardiovascular Safety of Dutasteride.
Skeldon SC; Macdonald EM; Law MR; Huang A; Paterson JM; Mamdani MM; Juurlink D
J Urol; 2017 May; 197(5):1309-1314. PubMed ID: 27866006
[TBL] [Abstract][Full Text] [Related]
9. Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.
Ross AE; Feng Z; Pierorazio PM; Landis P; Walsh PC; Carter HB; Trock BJ; Schaeffer EM
BJU Int; 2012 Sep; 110(5):651-7. PubMed ID: 22289613
[TBL] [Abstract][Full Text] [Related]
10. Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States.
DerSarkissian M; Xiao Y; Duh MS; Lefebvre P; Swensen AR; Bell CF
J Manag Care Spec Pharm; 2016 Oct; 22(10):1204-14. PubMed ID: 27668569
[TBL] [Abstract][Full Text] [Related]
11. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.
Kuiper JG; Bezemer ID; Driessen MT; Vasylyev A; Roehrborn CG; Penning-van Beest FJ; Herings RM
BMC Urol; 2016 Aug; 16(1):53. PubMed ID: 27580700
[TBL] [Abstract][Full Text] [Related]
12. 5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia.
Chou CH; Lin CL; Lin MC; Sung FC; Kao CH
J Endocrinol Invest; 2015 Jul; 38(7):799-805. PubMed ID: 25778849
[TBL] [Abstract][Full Text] [Related]
13. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.
Corona G; Tirabassi G; Santi D; Maseroli E; Gacci M; Dicuio M; Sforza A; Mannucci E; Maggi M
Andrology; 2017 Jul; 5(4):671-678. PubMed ID: 28453908
[TBL] [Abstract][Full Text] [Related]
14. Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.
Dutta A; Panja S; Virk RK; Kim JY; Zott R; Cremers S; Golombos DM; Liu D; Mosquera JM; Mostaghel EA; Barbieri CE; Mitrofanova A; Abate-Shen C
Eur Urol; 2017 Oct; 72(4):499-506. PubMed ID: 28385453
[TBL] [Abstract][Full Text] [Related]
15. Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality.
Björnebo L; Nordström T; Discacciati A; Palsdottir T; Aly M; Grönberg H; Eklund M; Lantz A
JAMA Oncol; 2022 Jul; 8(7):1019-1026. PubMed ID: 35587340
[TBL] [Abstract][Full Text] [Related]
16. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia.
Duan Y; Grady JJ; Albertsen PC; Helen Wu Z
Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):340-348. PubMed ID: 29316005
[TBL] [Abstract][Full Text] [Related]
17. Association of 5α-Reductase Inhibitors with Depression and Suicide: A Mini Systematic Review and Meta-analysis.
Uleri A; Cornu JN; Gobbo A; Herrmann TRW; De Nunzio C; Hashim H; Baboudjian M
Eur Urol Focus; 2024 Apr; ():. PubMed ID: 38692949
[TBL] [Abstract][Full Text] [Related]
18. A Focused Review on the Effects of Preoperative 5α-Reductase Inhibitors Treatment in Patients Undergoing Holmium Laser Enucleation of the Prostate: What Do We Know So Far?
Dimopoulos P; Christopoulos P; Kampantais S
J Endourol; 2018 Feb; 32(2):79-83. PubMed ID: 29161905
[TBL] [Abstract][Full Text] [Related]
19. A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride.
Antoniou T; Macdonald EM; Yao Z; Gomes T; Tadrous M; Ho JM; Mamdani MM; Juurlink DN;
BMC Musculoskelet Disord; 2018 May; 19(1):160. PubMed ID: 29789004
[TBL] [Abstract][Full Text] [Related]
20. Long-term use of 5α-reductase inhibitors and the risk of male breast cancer.
Duijnhoven RG; Straus SM; Souverein PC; de Boer A; Bosch JL; Hoes AW; De Bruin ML
Cancer Causes Control; 2014 Nov; 25(11):1577-82. PubMed ID: 25135615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
